117 related articles for article (PubMed ID: 38520334)
1. Detection of Single Nucleotide Polymorphisms of Circulating Tumor DNA by Strand Displacement Amplification Coupled with Liquid Chromatography.
Ma Z; Xu J; Hou W; Lei Z; Li T; Shen W; Yu H; Liu C; Zhang J; Tang S
Anal Chem; 2024 Apr; 96(13):5195-5204. PubMed ID: 38520334
[TBL] [Abstract][Full Text] [Related]
2. Analytical validation of the Target Selector ctDNA platform featuring single copy detection sensitivity for clinically actionable EGFR, BRAF, and KRAS mutations.
Poole JC; Wu SF; Lu TT; Vibat CRT; Pham A; Samuelsz E; Patel M; Chen J; Daher T; Singh VM; Arnold LJ
PLoS One; 2019; 14(10):e0223112. PubMed ID: 31581267
[TBL] [Abstract][Full Text] [Related]
3. Construction of a reference material panel for detecting
Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R
Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340
[TBL] [Abstract][Full Text] [Related]
6. Discrimination of the
Dekaliuk M; Qiu X; Troalen F; Busson P; Hildebrandt N
ACS Sens; 2019 Oct; 4(10):2786-2793. PubMed ID: 31577130
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation.
Cho MS; Park CH; Lee S; Park HS
PLoS One; 2020; 15(3):e0230622. PubMed ID: 32196518
[TBL] [Abstract][Full Text] [Related]
8. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
9. Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients.
Tran LS; Pham HT; Tran VU; Tran TT; Dang AH; Le DT; Nguyen SL; Nguyen NV; Nguyen TV; Vo BT; Dao HT; Nguyen NH; Tran TH; Nguyen CV; Pham PC; Dang-Mai AT; Dinh-Nguyen TK; Phan VH; Do TT; Truong Dinh K; Do HN; Phan MD; Giang H; Nguyen HN
PLoS One; 2019; 14(12):e0226193. PubMed ID: 31841547
[TBL] [Abstract][Full Text] [Related]
10. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
11. Multiplex Detection of Single Nucleotide Polymorphisms by Liquid Chromatography for Nonsmall Cell Lung Cancer Staging.
Song C; Ma Z; Zhang M; Liu C; Tang S; Zhang J; Song J; Yu H; Lee HK; Shen W
Anal Chem; 2024 Jan; 96(3):1054-1063. PubMed ID: 38190445
[TBL] [Abstract][Full Text] [Related]
12. Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies.
Solassol J; Vendrell JA; Senal R; Audran P; Leenhardt F; Quantin X
Lung Cancer; 2019 Jul; 133():45-47. PubMed ID: 31200827
[TBL] [Abstract][Full Text] [Related]
13. External Quality Assessment on Molecular Tumor Profiling with Circulating Tumor DNA-Based Methodologies Routinely Used in Clinical Pathology within the COIN Consortium.
van der Leest P; Rozendal P; Hinrichs J; van Noesel CJM; Zwaenepoel K; Deiman B; Huijsmans CJJ; van Eijk R; Speel EJM; van Haastert RJ; Ligtenberg MJL; van Schaik RHN; Jansen MPHM; Dubbink HJ; de Leng WW; Leers MPG; Tamminga M; van den Broek D; van Kempen LC; Schuuring E
Clin Chem; 2024 May; 70(5):759-767. PubMed ID: 38484302
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer.
Hamfjord J; Guren TK; Glimelius B; Sorbye H; Pfeiffer P; Dajani O; Lingjaerde OC; Tveit KM; Pallisgaard N; Spindler KG; Kure EH
Int J Cancer; 2021 Sep; 149(6):1385-1397. PubMed ID: 33961700
[TBL] [Abstract][Full Text] [Related]
15. KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.
Sclafani F; Chau I; Cunningham D; Hahne JC; Vlachogiannis G; Eltahir Z; Lampis A; Braconi C; Kalaitzaki E; De Castro DG; Wotherspoon A; Capdevila J; Glimelius B; Tarazona N; Begum R; Lote H; Hulkki Wilson S; Mentrasti G; Brown G; Tait D; Oates J; Valeri N
Sci Rep; 2018 Jan; 8(1):1445. PubMed ID: 29362371
[TBL] [Abstract][Full Text] [Related]
16. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.
Yang Y; Shen X; Li R; Shen J; Zhang H; Yu L; Liu B; Wang L
Oncotarget; 2017 Jul; 8(30):49773-49782. PubMed ID: 28572536
[TBL] [Abstract][Full Text] [Related]
17. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
[TBL] [Abstract][Full Text] [Related]
18. Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer.
Chow YP; Zainul Abidin N; Kow KS; Tho LM; Wong CL
PLoS One; 2022; 17(10):e0276161. PubMed ID: 36256645
[TBL] [Abstract][Full Text] [Related]
19. Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice.
Cho BC; Loong HHF; Tsai CM; Teo MLP; Kim HR; Lim SM; Jain S; Olsen S; Park K
Curr Oncol; 2022 Mar; 29(3):2154-2164. PubMed ID: 35323374
[TBL] [Abstract][Full Text] [Related]
20. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance.
O'Kane GM; Liu G; Stockley TL; Shabir M; Zhang T; Law JH; Le LW; Sacher A; Shepherd FA; Bradbury PA; Leighl NB
Lung Cancer; 2019 May; 131():86-89. PubMed ID: 31027703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
